Combining Anti-tumor Alkyl-Phospholipid Analogs and Radiotherapy: Rationale and Clinical Outlook

Author(s): Marcel Verheij, Wouter H. Moolenaar, Wim J. van Blitterswijk.

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 14 , Issue 4 , 2014

Become EABM
Become Reviewer

Abstract:

Our improved understanding of the molecular processes that determine cellular sensitivity to ionizing radiation has accelerated the identification of new targets for intervention. Indeed, novel agents have become available for combined clinical use to overcome radioresistance and increase the therapeutic ratio of radiotherapy. Synthetic alkyl-phospholipid analogs (APLs), such as edelfosine, ilmofosine, miltefosine, perifosine and erucylphosphocholine, are a novel class of anti-tumor agents that target cell membranes to induce growth arrest and apoptosis. In addition, APLs strongly enhance the cytotoxic effect of radiation in preclinical models making these compounds attractive candidates as clinical radiosensitizers. In this review, we will discuss mechanisms of action underlying the rationale to combine APLs with radiotherapy and highlight the clinical perspective of this novel combined modality treatment.

Keywords: Alkyl-phospholipids, anti-cancer agents, apoptosis, (Pre-)clinical, radiosensitizer, radiotherapy, signal transduction.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 4
Year: 2014
Page: [618 - 628]
Pages: 11
DOI: 10.2174/1871520614666140309224145
Price: $65

Article Metrics

PDF: 33